For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...

At the end of the day, weight loss options, like any other health-related decisions, are very personal and must be made on a ...

The company reported progress in external distribution agreements, including initiatives to co-package pen needles with generic GLP-1 drugs ... $110 million in debt reduction for FY2025.

After just a few years on the market, a new wave of GLP-1 drugs approved for weight loss have upended what we know about obesity. By now, these are household names: Mounjaro. Wegovy. Zepbound ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...

BUFFALO, N.Y. — A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision ... She adds that a rapid reduction in blood glucose levels, which is the ...

The initiative’s reported $1 billion daily reduction in federal spending represents the first phase of its implementation. DOGE’s next target of $4 billion in daily cuts shows an expansion of the ...

The relative reduction in major adverse cardiovascular events (MACE) with SGLT2 inhibitors was greater in older versus younger participants, but the relative reduction in MACE with GLP-1 receptor ...

This means that if a person with diabetes switches to a high-protein diet, any therapeutic benefit is probably due to the concurrent reduction and closer regulation ... studies have found that people ...

GLP-1: Glucagon-like peptide-1 ... Published and preliminary data have shown once-weekly exenatide to result in greater A1c reduction than exenatide twice daily; and as a second- or third-line ...

Trulicity is a GLP-1 agonist that helps manage type 2 diabetes and has shown to aid in weight loss. Clinical trials showed that Trulicity helped reduce A1C levels by 1.5% to 1.9% over 24 weeks.